Hacked        Development in the syllabus of Pharmaceutical Marketing & Management that is studied in the Bachelor of Pharmacy course of Bangladeshi Universities.        LOSECTIL stands beside acid survivors        Vitamin D Levels Linked to Parkinson's Symptoms        Keeping the newborn warm at home at winter        It’s time to prevent cervical cancer        Huge Rise in CT, MRI, Ultrasound Scan Use: Study        Exercise May Delay Early Aging of People With Diabetes        Alzheimer's Drug Shows Some Promise in Trials        Obesity, Depression Blamed for Daytime Sleepiness Epidemic     

Member Sign In
Forgot Your
Username & Password?


Not a Member?
Please Sign Up Here


 
 
Sr. Executive / Executive, Production; THE IBN SINA PHARMACEUTICAL IND LTD

 
Approval of Yervoy Injection (ipilimumab) by FDA
Brand Name: Yervoy Injection
Generic Name: ipilimumab
Company Name: Bristol-Myers Squibb
Date of Approval: March 25, 2011
Treatmant for: Melanoma - Metastatic
The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer. Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and about 8,700 people died from the disease, according to the National Cancer Institute.

“Late-stage melanoma is devastating, with very few treatment options for patients, none of which previously prolonged a patient’s life,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research. "Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live longer by taking this treatment."

Yervoy is a monoclonal antibody that blocks a molecule known as cytotoxic T-lymphocyte antigen or CTLA-4. CTLA-4 may play a role in slowing down or turning off the body’s immune system, affecting its ability to fight off cancerous cells. Yervoy may work by allowing the body’s immune system to recognize, target, and attack cells in melanoma tumors. The drug is administered intravenously.

Yervoy’s safety and effectiveness were established in a single international study of 676 patients with melanoma. All patients in the study had stopped responding to other FDA-approved or commonly used treatments for melanoma. In addition, participants had disease that had spread or that could not be surgically removed.

The study was designed to measure overall survival, the length of time from when this treatment started until a patient's death. The randomly assigned patients received Yervoy plus an experimental tumor vaccine called gp100, Yervoy alone, or the vaccine alone.

Those who received the combination of Yervoy plus the vaccine or Yervoy alone lived an average of about 10 months, while those who received only the experimental vaccine lived an average of 6.5 months.

Common side effects that can result from autoimmune reactions associated with Yervoy use include fatigue, diarrhea, skin rash, endocrine deficiencies (gland or hormone), and inflammation of the intestines (colitis). Severe to fatal autoimmune reactions were seen in 12.9 percent of patients treated with Yervoy. When severe side effects occurred, Yervoy was stopped and corticosteroid treatment was started. Not all patients responded to this treatment. Patients who did respond in some cases did not see any improvement for several weeks.

Due to the unusual and severe side effects associated with Yervoy, the therapy is being approved with a Risk Evaluation and Mitigation Strategy to inform health care professionals about these serious risks. A medication guide will also be provided to patients to inform them about the therapy's potential side effects. Yervoy is marketed by New York City-based Bristol-Myers Squibb.
Note: To know more please go to the following sources.
Update: 2011-03-28
Source: Drugs.com & FDA
 
Other FDA Approval
Approval of Tradjenta Tablets (linagliptin) by FDA
Approval of Xalkori Capsules (crizotinib) by FDA
Approval of Gadavist Injection (gadobutrol) by FDA
Approval of vandetanib Tablets (vandetanib ) by FDA
Approval of Brilinta Tablets (ticagrelor) by FDA
Approval of Zelboraf Tablets (vemurafenib) by FDA
Approval of Arcapta Neohaler (Indacaterol) by FDA
Approval of Adcetris (brentuximab vedotin) by FDA
See all the FDA Approval